Media headlines about Cryolife (NYSE:CRY) have trended somewhat positive this week, AlphaOne Sentiment reports. The research firm, a subsidiary of Accern, scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cryolife earned a media sentiment score of 0.03 on AlphaOne’s scale. AlphaOne also assigned media coverage about the medical equipment provider an impact score of 33 out of 100, meaning that recent press coverage is unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news headlines that may have impacted AlphaOne Sentiment’s scoring:

Cryolife (NYSE:CRY) traded up 0.27% on Wednesday, hitting $18.35. 38,651 shares of the company’s stock traded hands. The stock has a market cap of $595.24 million, a PE ratio of 60.76 and a beta of 1.23. Cryolife has a one year low of $11.11 and a one year high of $20.15. The stock has a 50-day moving average of $16.31 and a 200-day moving average of $17.72.

Cryolife (NYSE:CRY) last posted its quarterly earnings results on Wednesday, April 26th. The medical equipment provider reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The firm had revenue of $45.10 million for the quarter, compared to analyst estimates of $44.64 million. Cryolife had a net margin of 6.00% and a return on equity of 8.37%. Cryolife’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. On average, equities analysts forecast that Cryolife will post $0.39 earnings per share for the current fiscal year.

Several research firms have recently commented on CRY. Northland Securities restated a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a research note on Friday, April 28th. Zacks Investment Research lowered Cryolife from a “hold” rating to a “sell” rating in a research note on Thursday, February 23rd. Ladenburg Thalmann Financial Services upgraded Cryolife from a “neutral” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Friday, February 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $23.50 target price on shares of Cryolife in a report on Monday, January 23rd. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $19.67.

COPYRIGHT VIOLATION WARNING: “Cryolife (CRY) Receives Daily News Impact Rating of 0.03” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at

In related news, VP Scott B. Capps sold 11,083 shares of the business’s stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $16.40, for a total transaction of $181,761.20. Following the transaction, the vice president now directly owns 128,477 shares in the company, valued at $2,107,022.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.08% of the company’s stock.

About Cryolife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

5 Day Chart for NYSE:CRY

Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with's FREE daily email newsletter.